3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Conditions
Neoplasms
9
Carcinoma, Non-Small-Cell Lung
9
Melanoma
7
Prostatic Neoplasms
5
Ovarian Neoplasms
5
Neoplasm Metastasis
5
Recurrence
4
Carcinoma, Renal Cell
4
Squamous Cell Carcinoma of Head and Neck
3
Pancreatic Neoplasms
3
Head and Neck Neoplasms
3
Colorectal Neoplasms
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Lung Neoplasms
2
Glioma
2
Fallopian Tube Neoplasms
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Merkel Cell
2
Breast Neoplasms
2
Uterine Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Solid Tumor
1
Skin Neoplasms
1
Sarcoma
1
Mycosis Fungoides
1
Multiple Myeloma
1
Interventions
Sorafenib
7
Radiosurgery
6
Bevacizumab
6
pembrolizumab
4
Oxaliplatin
4
Cryosurgery
4
atezolizumab
3
Radiotherapy, Conformal
3
Nivolumab
3
Ipilimumab
3
Fluorouracil
3
Cyclophosphamide
3
tremelimumab
2
spartalizumab
2
lenvatinib
2
fludarabine
2
Leucovorin
2
Injections
2
Gemcitabine
2
Everolimus
2
Epirubicin
2
Doxorubicin
2
Celecoxib
2
Carboplatin
2
Capecitabine
2
yttrium chloride
1
vofatamab
1
toripalimab
1
tocilizumab
1
sapanisertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Liver Neoplasms
×
cemiplimab
×
Clear all
NCT06923761
2026-01-28
EMITT-1
Grey Wolf Therapeutics
Phase 1/2
Recruiting
300 enrolled